| Article | Date | Source |
|---|
| Intercept Pharmaceuticals Announces Initiation of Phase 2 NASH Trial of OCA in Japan | January 08, 2013 | BioSpace - Breaking News |
| Intercept Pharmaceuticals Announces Pricing of Initial Public Offering | October 11, 2012 | BioSpace - Breaking News |
| Cerus to Partner with American Red Cross and Blood Systems Incorporated to Commercialize INTERCEPT Plasma for Thrombotic Thrombocytopenic Purpura (TTP) Orphan Indication | September 11, 2012 | FDA News - Business Wire |
| Intercept Pharmaceuticals Files for $75 Million IPO | September 05, 2012 | BioSpace |
| Intercept Pharma files for $75M IPO to back PhIII liver drug | September 05, 2012 | FierceBiotech |
| Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering | September 04, 2012 | Pharma News - PR Newswire |
| Cerus Announces First INTERCEPT Blood System Customer in Turkey | August 07, 2012 | Biotech News - Business Wire |
| Cerus Announces First INTERCEPT Platelet System Customer in Austria | April 18, 2012 | Biotech News - Business Wire |
| Cerus Submits Investigational Device Exemption (IDE) Supplement to FDA for Phase III INTERCEPT Red Blood Cell Study | March 21, 2012 | Biotech News - Business Wire |
| Cerus and Ilex BioTech Report INTERCEPT Platelet and Plasma System Approvals in Israel | February 01, 2012 | Biotech News - Business Wire |
| Cerus Announces Contracts for 19 New INTERCEPT Blood System Illuminators in Russia | December 06, 2011 | Biotech News - Business Wire |
| Intercept nails $165M diabetes pact with Servier | August 09, 2011 | FierceBiotech |
| Intercept Pharmaceuticals, Servier Announce up to $163 Million Agreement for TGR5 Research Program in Type 2 Diabetes | August 09, 2011 | BioSpace |
| Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes | August 09, 2011 | Biotech News - PR Newswire |
| Cerus Corporation and Ilex Biotech LTD Initiate Distribution Agreements for the INTERCEPT Blood System in South Africa and Israel | June 09, 2011 | Biotech News - Business Wire |
| Airport authorities intercept illegal consignment of pain-killers | May 26, 2011 | Pharmaceutical - Moreover |
| Dainippon Sumitomo Pharma lands into a deal with Intercept Pharmaceutical | April 04, 2011 | Pharmaceutical - Moreover |
| Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis | March 31, 2011 | Biotech News - PR Newswire |
| Intercept lands $315M Asian pact for liver disease drug | March 30, 2011 | FierceBiotech |
| Dainippon Sumitomo Pharma Co., Ltd. and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease; Pays $15 Million and up to $300 Million | March 30, 2011 | BioSpace |
| Dainippon Sumitomo Pays Intercept $15M for License to Phase III-Stage Liver Disease Drug | March 30, 2011 | Inside Industry - Gen |
| Dainippon Sumitomo, Intercept in Liver Drug Pact | March 30, 2011 | Contract Pharma |
| Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease | March 30, 2011 | Pharma News - PR Newswire |
| Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals' Obeticholic Acid (INT-747) in NASH | March 29, 2011 | Pharma News - PR Newswire |
| Cerus Corporation's INTERCEPT Plasma Granted Orphan Drug Designation for Treatment of Thrombotic Thrombocytopenic Purpura (TTP) | February 16, 2011 | BioSpace - Breaking News |
| Cerus' INTERCEPT Plasma Granted Orphan Drug Designation for Treatment of Thrombotic Thrombocytopenic Purpura (TTP) | February 16, 2011 | FDA News - Business Wire |
| Cerus’ INTERCEPT Blood System for Plasma Receives Swiss Approval | November 16, 2010 | Biotech News - Business Wire |
| CSL Limited and Cerus Corporation Enter Distribution Agreement for the INTERCEPT Blood System in Australia and New Zealand | October 12, 2010 | Pharma News - Business Wire |
| Cerus' INTERCEPT Platelet System Succeeds in 3-Year French Study | September 27, 2010 | Pharma News - Business Wire |
| Whittemore Peterson Institute and Cerus Corporation Announce Inactivation of XMRV in Platelets and Red Blood Cells by the INTERCEPT Blood System | September 07, 2010 | BioSpace - Breaking News |
| Whittemore Peterson Institute and Cerus Announce Inactivation of XMRV in Platelets and Red Blood Cells by the INTERCEPT Blood System | September 07, 2010 | Biotech News - Business Wire |
| Cerus and the Swiss Red Cross Report Successful Outcome of INTERCEPT Blood System Platelet Study | September 02, 2010 | Biotech News - Business Wire |
| Cerus Corporation Signs Agreement to Acquire INTERCEPT Blood System Asian Commercial Rights from BioOne | August 25, 2010 | BioSpace - Breaking News |
| Cerus Signs Agreement to Acquire INTERCEPT Blood System Asian Commercial Rights from BioOne | August 24, 2010 | Pharma News - Business Wire |
| Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH) | July 28, 2010 | Biotech News - PR Newswire |
| Whittemore Peterson Institute and Cerus Confirm Inactivation of XMRV by the INTERCEPT Blood System | May 18, 2010 | Biotech News - Business Wire |
| Intercept Pharmaceuticals Presents Positive Phase II Results from Study of INT-747 Therapy in Primary Biliary Cirrhosis at EASL Company Also Presents Data on Novel Dual FXR/TGR5 Agonist INT-767 | April 13, 2010 | BioSpace - Breaking News |
| Intercept Pharmaceuticals Presents Positive Phase II Results from Study of INT-747 Therapy in Primary Biliary Cirrhosis at EASL | April 13, 2010 | Clinical Trials - PR Newswire |
| Intercept Pharmaceuticals, Inc.: Series B $25M | April 12, 2010 | OnBioVC |
| Cerus Signs Agreement with Swiss Red Cross for Deployment of the INTERCEPT Blood System for Platelets | March 31, 2010 | Biotech News - Business Wire |
| Data Presented at International Haemovigilance Seminar Confirm Safety of Cerus' INTERCEPT Blood System for Platelets and Plasma | February 17, 2010 | Clinical Trials - Business Wire |
| Cerus to Collaborate with French National Transfusion Service on INTERCEPT Red Blood Cell Development | February 09, 2010 | Biotech News - Business Wire |
| Cerus Corporation Reports Positive Outcome of Phase 1 Clinical Trial of INTERCEPT Red Blood Cells | February 09, 2010 | Biotech News - Business Wire |
| Intercept Pharmaceuticals Raises $25 Million Series B Financing; Assumes Role of Chairman | January 25, 2010 | BioSpace - Breaking News |
| Intercept Pharmaceuticals Scores $25M in Series B Financing | January 25, 2010 | GEN News Highlights |
| Intercept Pharma hauls in $25M Series B | January 25, 2010 | FierceBiotech |
| Intercept Pharmaceuticals Raises $25 Million Series B Financing | January 25, 2010 | Biotech News - PR Newswire |
| Cerus Corporation Reports Positive Outcome in European Study of 7-Day INTERCEPT Platelets | January 14, 2010 | Biotech News - Business Wire |
